To assess the impact of multimodal speech-gesture training on patients’ communication abilities, investigators conducted a randomized waiting list-controlled pilot trial at a university in Marburg, Germany.
The researchers conducted secondary analysis of a multi-site CET trial using 86 individuals recently diagnosed with a schizophrenia spectrum disorder.
The approval was based on data from the phase 3 SERENITY I and II studies that evaluated Igalmi for the acute treatment of agitation associated with schizophrenia and bipolar disorders I and II, respectively.
A clinical decisions support system provides personalized treatment recommendations on lowering cardiovascular risk factors in patients with schizophrenia, schizoaffective disorder, and bipolar disorder.
The results of a genome-wide association study may help researchers develop more tailored treatments to help patients who don’t respond to conventional antipsychotic medications.
Three-quarters of all psychiatric disorders occur by early adulthood (mid-20s). This fact suggests that bio-psychosocial factors occurring from the fetal period through early adulthood could play a crucial role in risk. This nonsystematic review sought to synthesize key epidemiological evidence of relevant risk factors.
With people who have major psychiatric disorders being more likely to have comorbidities which could lead to worse results concerning COVID-19, researchers using a US database assessed the odds of testing positive for COVID-19, as well as mortality from COVID-19.
The approval was based on data from an ongoing phase 3 trial evaluating the safety and tolerability of brexpiprazole as maintenance treatment of 194 patients aged 13 to 17 years with schizophrenia.
Lybalvi is an atypical antipsychotic comprised of samidorphan co-formulated with olanzapine in a single bilayer tablet.
The Food and Drug Administration has approved Invega Hafyera™ (paliperidone palmitate), an every 6-month injection, for the treatment of schizophrenia in adults. Invega Hafyera is a long-acting atypical antipsychotic that is administered as a gluteal intramuscular injection by a health care professional. Prior to initiating treatment with Invega Hafyera, patients must have been adequately treated…
